(SIGA) SIGA Technologies - Ratings and Ratios
Antiviral, Pharmaceuticals, Smallpox Treatment, Medications
SIGA EPS (Earnings per Share)
SIGA Revenue
Description: SIGA SIGA Technologies
SIGA Technologies Inc (NASDAQ:SIGA) is a commercial-stage pharmaceutical company specializing in the health security market, primarily in the United States. Its flagship product, TPOXX, is an antiviral medication designed to treat human smallpox disease caused by the variola virus. With its incorporation in 1995 and headquarters in New York, the company has established a niche in the pharmaceutical industry.
From a financial perspective, SIGA has demonstrated key performance indicators (KPIs) that highlight its market position. The companys market capitalization stands at $465.80 million, indicating a moderate size within the pharmaceutical sector. Its price-to-earnings ratio (P/E) is 9.73, and the forward P/E is 9.89, suggesting a relatively stable earnings outlook. Additionally, the return on equity (RoE) of 25.24% is a strong indicator of the companys ability to generate profits from shareholders equity. These metrics collectively suggest that SIGA is a financially stable entity within its industry.
Considering the companys product portfolio and financial health, its essential to analyze its growth prospects. As TPOXX is SIGAs lead product, its commercial success is crucial to the companys overall performance. The antiviral drugs market potential, coupled with the companys strategic positioning in the health security market, could drive future growth. Furthermore, the companys ability to maintain a strong RoE and manage its P/E ratio effectively will be vital in attracting and retaining investors.
To further evaluate SIGAs investment potential, its crucial to examine its competitive landscape, research and development (R&D) pipeline, and overall industry trends. The pharmaceutical industry is highly competitive and subject to regulatory changes, so SIGAs adaptability and innovation will be key to its long-term success. By focusing on its core strengths and expanding its product offerings, SIGA can potentially enhance its market position and drive shareholder value.
SIGA Stock Overview
| Market Cap in USD | 609m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 1997-09-09 |
SIGA Stock Ratings
| Growth Rating | 16.8% |
| Fundamental | 84.3% |
| Dividend Rating | 88.0% |
| Return 12m vs S&P 500 | -16.4% |
| Analyst Rating | - |
SIGA Dividends
| Dividend Yield 12m | 8.41% |
| Yield on Cost 5y | 11.79% |
| Annual Growth 5y | 10.06% |
| Payout Consistency | 98.8% |
| Payout Ratio | 52.5% |
SIGA Growth Ratios
| Growth Correlation 3m | 89.6% |
| Growth Correlation 12m | 10.3% |
| Growth Correlation 5y | 26.1% |
| CAGR 5y | 10.09% |
| CAGR/Max DD 5y | 0.12 |
| Sharpe Ratio 12m | -0.08 |
| Alpha | -22.83 |
| Beta | 1.235 |
| Volatility | 54.81% |
| Current Volume | 324.1k |
| Average Volume 20d | 482.5k |
| Stop Loss | 7.7 (-6.2%) |
| Signal | -0.92 |
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income (82.2m TTM) > 0 and > 6% of Revenue (6% = 10.8m TTM) |
| FCFTA 0.51 (>2.0%) and ΔFCFTA 12.27pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 114.9% (prev 89.67%; Δ 25.27pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.51 (>3.0%) and CFO 119.1m > Net Income 82.2m (YES >=105%, WARN >=100%) |
| Net Debt (-181.9m) to EBITDA (102.5m) ratio: -1.77 <= 3.0 (WARN <= 3.5) |
| Current Ratio 10.09 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (71.7m) change vs 12m ago -0.01% (target <= -2.0% for YES) |
| Gross Margin 73.13% (prev 79.83%; Δ -6.70pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 83.95% (prev 89.77%; Δ -5.83pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' 7.27
| (A) 0.88 = (Total Current Assets 229.2m - Total Current Liabilities 22.7m) / Total Assets 235.3m |
| (B) -0.13 = Retained Earnings (Balance) -31.3m / Total Assets 235.3m |
| (C) 0.48 = EBIT TTM 102.1m / Avg Total Assets 214.0m |
| (D) -1.20 = Book Value of Equity -31.3m / Total Liabilities 26.0m |
| Total Rating: 7.27 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 84.28
| 1. Piotroski 4.50pt = -0.50 |
| 2. FCF Yield 27.67% = 5.0 |
| 3. FCF Margin 66.25% = 7.50 |
| 4. Debt/Equity 0.02 = 2.50 |
| 5. Debt/Ebitda 0.04 = 2.50 |
| 6. ROIC - WACC 28.60% = 12.50 |
| 7. RoE 40.55% = 2.50 |
| 8. Rev. Trend 19.02% = 0.95 |
| 9. Rev. CAGR 4.32% = 0.54 |
| 10. EPS Trend 17.84% = 0.45 |
| 11. EPS CAGR 3.41% = 0.34 |
What is the price of SIGA shares?
Over the past week, the price has changed by -6.17%, over one month by +13.87%, over three months by +34.81% and over the past year by -1.56%.
Is SIGA Technologies a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SIGA is around 7.99 USD . This means that SIGA is currently overvalued and has a potential downside of -2.68%.
Is SIGA a buy, sell or hold?
What are the forecasts/targets for the SIGA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 17.5 | 113.5% |
| Analysts Target Price | 17.5 | 113.5% |
| ValueRay Target Price | 9.1 | 10.6% |
Last update: 2025-08-19 02:48
SIGA Fundamental Data Overview
CCE Cash And Equivalents = 182.5m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 7.4561
P/E Forward = 16.3399
P/S = 3.3882
P/B = 2.9079
Beta = 0.951
Revenue TTM = 179.6m USD
EBIT TTM = 102.1m USD
EBITDA TTM = 102.5m USD
Long Term Debt = 3.30m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 570.4k USD (from shortTermDebt, last quarter)
Debt = 3.87m USD (Calculated: Short Term 570.4k + Long Term 3.30m)
Net Debt = -181.9m USD (from netDebt column, last quarter)
Enterprise Value = 430.1m USD (608.7m + Debt 3.87m - CCE 182.5m)
Interest Coverage Ratio = unknown (Ebit TTM 102.1m / Interest Expense TTM 0.0)
FCF Yield = 27.67% (FCF TTM 119.0m / Enterprise Value 430.1m)
FCF Margin = 66.25% (FCF TTM 119.0m / Revenue TTM 179.6m)
Net Margin = 45.75% (Net Income TTM 82.2m / Revenue TTM 179.6m)
Gross Margin = 73.13% ((Revenue TTM 179.6m - Cost of Revenue TTM 48.3m) / Revenue TTM)
Tobins Q-Ratio = -13.75 (set to none) (Enterprise Value 430.1m / Book Value Of Equity -31.3m)
Interest Expense / Debt = 23.01% (Interest Expense 890.6k / Debt 3.87m)
Taxrate = 22.16% (from yearly Income Tax Expense: 16.9m / 76.1m)
NOPAT = 79.5m (EBIT 102.1m * (1 - 22.16%))
Current Ratio = 10.09 (Total Current Assets 229.2m / Total Current Liabilities 22.7m)
Debt / Equity = 0.02 (Debt 3.87m / last Quarter total Stockholder Equity 209.3m)
Debt / EBITDA = 0.04 (Net Debt -181.9m / EBITDA 102.5m)
Debt / FCF = 0.03 (Debt 3.87m / FCF TTM 119.0m)
Total Stockholder Equity = 202.7m (last 4 quarters mean)
RoA = 34.92% (Net Income 82.2m, Total Assets 235.3m )
RoE = 40.55% (Net Income TTM 82.2m / Total Stockholder Equity 202.7m)
RoCE = 49.57% (Ebit 102.1m / (Equity 202.7m + L.T.Debt 3.30m))
RoIC = 39.22% (NOPAT 79.5m / Invested Capital 202.7m)
WACC = 10.62% (E(608.7m)/V(612.5m) * Re(10.57%)) + (D(3.87m)/V(612.5m) * Rd(23.01%) * (1-Tc(0.22)))
Shares Correlation 5-Years: -70.0 | Cagr: -1.05%
Discount Rate = 10.57% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 73.67% ; FCFE base≈100.9m ; Y1≈124.5m ; Y5≈212.4m
Fair Price DCF = 33.15 (DCF Value 2.37b / Shares Outstanding 71.6m; 5y FCF grow 25.0% → 3.0% )
Revenue Correlation: 19.02 | Revenue CAGR: 4.32%
Rev Growth-of-Growth: -0.79
EPS Correlation: 17.84 | EPS CAGR: 3.41%
EPS Growth-of-Growth: -3.57
Additional Sources for SIGA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle